Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 95

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 95
---
 a
robust safety, efficacy, and stability profile for the lead formulation. Clinical trials are planned to commence by the second half of
2027.

We believe that our novel Nano-Candesartan
approach addresses the unmet medical needs of millions of cancer patients worldwide and has the potential to achieve significant market
success as a combination therapy, synergistic with leading anticancer therapeutics.

The global anticancer therapeutics market is undergoing
rapid growth, driven by the rising incidence of cancer and advancements in treatment technologies. According to The Brainy Insights, the
market was valued at approximately $222.71 billion in 2023 and is projected to reach around $885.44 billion by 2033, reflecting a compound
annual growth rate (CAGR) of 14.80% from 2024 to 2033.

Initially, we plan to target pancreatic cancer, a highly aggressive
malignancy with extremely limited treatment options and a very poor prognosis. Current standard therapies offer only modest survival
benefits, and there remains a significant unmet need for more effective and better-tolerated treatments.

The Liposomal ARB is intended to be used in
combination with standard-of-care agents such as Gemcitabine (Gemzar) and Nab-Paclitaxel, with the goal of enhancing therapeutic efficacy
by modulating the tumor microenvironment. Given the urgent clinical need and limited competitive landscape, this indication represents
a meaningful commercial opportunity with potential for expedited development pathways.

Clinical Background and Unmet Need

Pancreatic ductal adenocarcinoma (PDAC) remains
one of the deadliest malignancies with a 5-year survival rate under 11% [1]. Standard-of-care for advanced PDAC includes combination
chemotherapy with Gemcitabine (Gemzar®) and Nab-Paclitaxel (Abraxane®), which provides limited survival benefit. ARBs (angiotensin
receptor blockers), including Candesartan, have shown promise as tumor microenvironment modulators, potentially enhancing drug delivery
and efficacy when used in combination therapies.

Liposomal-ARB (IV formulation of Nano-Candesartan) is being developed
as an adjunct to enhance the therapeutic effect of Gemzar/NAB by modulating tumor stroma, increasing intratumoral perfusion, and improving
drug uptake.

<div align='center'>59</div>

Pricing Benchmark and Market Assumptions

To estimate the value of a liposomal-ARB formulation,